Operating loss was $8.8m, compared to $7.09m for the comparable period in 2009.
For the nine months ended 30 September 2010, Chelsea has posted a net loss of $24.94m, or $0.65 loss per diluted share, compared to net loss of $19.81m, or $0.64 loss per diluted share, for the year ago period.
Operating loss was $25.06m for the nine months ended 30 September 2010, compared to $24.35m for the year ago period.
Chelsea president and CEO Simon Pedder said that the last few months have been momentous for Chelsea as they reported favorable findings from Study 301 demonstrating that Northera provided significant symptomatic relief of neurogenic orthostatic hypotension, continued to enroll patients into Study 306 at a better than expected pace, and substantively strengthened their balance sheet.
"While collectively these accomplishments should put us in a strong position to complete our first NDA filing in 2011, we believe they are only just the beginning of a transformative period for Chelsea," Pedder said.
"Over the next several quarters, we eagerly anticipate reporting data from five on-going clinical trials including our Phase III trial of Northera in NOH associated with Parkinson’s disease; our Phase II trial of CH-4051 in rheumatoid arthritis; our Phase II trial of droxidopa/carbidopa combination therapy in fibromyalgia; as well as from the investigator-led Phase II trials of droxidopa/carbidopa combination therapy in adult attention deficit hyperactivity disorder and droxidopa monotherapy in chronic fatigue syndrome."